STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G] Oric Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: Percentage calculated based on 97,119,670 shares of Common Stock outstanding on July 29, 2025, as disclosed by the Issuer to the reporting person.


SCHEDULE 13G




Comment for Type of Reporting Person: Percentage calculated based on 97,119,670 shares of Common Stock outstanding on July 29, 2025, as disclosed by the Issuer to the reporting person.


SCHEDULE 13G




Comment for Type of Reporting Person: Percentage calculated based on 97,119,670 shares of Common Stock outstanding on July 29, 2025, as disclosed by the Issuer to the reporting person.


SCHEDULE 13G



EcoR1 Capital, LLC
Signature:/s/ Oleg Nodelman
Name/Title:Manager
Date:08/05/2025
Oleg Nodelman
Signature:/s/ Oleg Nodelman
Name/Title:Reporting person
Date:08/05/2025
EcoR1 Capital Fund Qualified, L.P.
Signature:/s/ Oleg Nodelman
Name/Title:Manager of the General Partner, EcoR1 Capital, LLC
Date:08/05/2025
Exhibit Information

EXHIBIT 99.1 - AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G

Oric Pharmaceuticals, Inc.

NASDAQ:ORIC

ORIC Rankings

ORIC Latest News

ORIC Latest SEC Filings

ORIC Stock Data

1.13B
87.20M
6.94%
99.21%
8.42%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO